


**Product Name** : JNJ-42226314  
**Cat. No.** : PC-72112  
**CAS No.** : 1252765-13-1  
**Molecular Formula** : C<sub>26</sub>H<sub>24</sub>FN<sub>5</sub>O<sub>2</sub>S  
**Molecular Weight** : 489.569  
**Target** : Monoacylglycerol Lipase (MAGL)  
**Solubility** : 10 mM in DMSO



## Biological Activity

JNJ-42226314 (JNJ42226314) is a potent, highly selective and reversible **MAGL** inhibitor with IC<sub>50</sub> of 1.13 nM (hMAGL). JNJ-42226314 displays high selectivity against the serine hydrolase superfamily, as well as a panel of 50 binding assays for ion channels and receptors, including CB1 and CB2. JNJ-42226314 also shows MAGL across species (mouse, rat MAGL IC<sub>50</sub>=1 nM).

JNJ-42226314 inhibits MAGL in a competitive mode with respect to the 2-AG substrate.

JNJ-42226314 time- and dose-dependently bound to MAGL, indirectly led to CB1 occupancy by raising 2-AG levels, and raised norepinephrine levels in cortex in rodent brain.

JNJ-42226314 exhibited antinociceptive efficacy in both the rat complete Freund's adjuvant-induced radiant heat hypersensitivity and chronic constriction injury-induced cold hypersensitivity models of inflammatory and neuropathic pain, respectively.

JNJ-42226314 induced hippocampal synaptic depression, altered sleep onset, and decreased electroencephalogram gamma power at 30 mg/kg, significantly increased 2-AG and norepinephrine levels, and produced neuropathic antinociception without synaptic depression at 3 mg/kg.

## References

Ryan M Wyatt, et al. *J Pharmacol Exp Ther*. 2020 Mar;372(3):339-353.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com